What's in The New York Eye & Ear Infirmary's pipeline?

The New York Eye & Ear Infirmary has 2 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with The New York Eye & Ear Infirmary's portfolio?

Top competitors by shared drug class: Beni-Suef University.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/the-new-york-eye-ear-infirmary.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

The New York Eye & Ear Infirmary — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The New York Eye & Ear Infirmary pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
PRFM treatment	PRFM treatment	phase 3	Regenerative medicine / Autologous cell therapy		Ophthalmology / Regenerative Medicine

Therapeutic area mix

Ophthalmology / Regenerative Medicine · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Beni-Suef University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for The New York Eye & Ear Infirmary:

Cite this brief

Drug Landscape (2026). The New York Eye & Ear Infirmary — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/the-new-york-eye-ear-infirmary. Accessed 2026-05-17.